WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 510225
CAS#: 290315-45-6
Description: BMS-299897 is a gamma-secretase inhibitor that has the potential for treatment of Alzheimer's disease.
MedKoo Cat#: 510225
Name: BMS-299897
CAS#: 290315-45-6
Chemical Formula: C24H21ClF3NO4S
Exact Mass: 511.08319
Molecular Weight: 511.94
Elemental Analysis: C, 56.31; H, 4.13; Cl, 6.93; F, 11.13; N, 2.74; O, 12.50; S, 6.26
BMS-299897, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: BMS299897; BMS 299897; BMS-299897.
IUPAC/Chemical Name: (R)-4-(2-(1-(4-chloro-N-(2,5-difluorophenyl)phenylsulfonamido)ethyl)-5-fluorophenyl)butanoic acid
InChi Key: IZAOBRWCUGOKNH-OAHLLOKOSA-N
InChi Code: InChI=1S/C24H21ClF3NO4S/c1-15(21-11-7-18(26)13-16(21)3-2-4-24(30)31)29(23-14-19(27)8-12-22(23)28)34(32,33)20-9-5-17(25)6-10-20/h5-15H,2-4H2,1H3,(H,30,31)/t15-/m1/s1
SMILES Code: O=C(O)CCCC1=CC(F)=CC=C1[C@H](N(C2=CC(F)=CC=C2F)S(=O)(C3=CC=C(Cl)C=C3)=O)C
The following data is based on the product molecular weight 511.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Meunier J, Villard V, Givalois L, Maurice T. The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1-42 seeding and short-term memory deficits in the Aβ25-35 mouse model of Alzheimer's disease. Eur J Pharmacol. 2013 Jan 5;698(1-3):193-9. doi: 10.1016/j.ejphar.2012.10.033. Epub 2012 Nov 2. PubMed PMID: 23123349.
2: Zheng M, Wang J, Lubinski J, Flint OP, Krishna R, Yao M, Pursley JM, Thakur A, Boulton DW, Santone KS, Barten DM, Anderson JJ, Felsenstein KM, Hansel SB. Studies on the pharmacokinetics and metabolism of a gamma-secretase inhibitor BMS-299897, and exploratory investigation of CYP enzyme induction. Xenobiotica. 2009 Jul;39(7):544-55. doi: 10.1080/00498250902928555. PubMed PMID: 19480557.
3: Xue YJ, Pursley J, Arnold M. Liquid-liquid extraction of strongly protein bound BMS-299897 from human plasma and cerebrospinal fluid, followed by high-performance liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal. 2007 Apr 11;43(5):1728-36. Epub 2007 Jan 3. PubMed PMID: 17204392.
4: Zhang D, Hanson R, Roongta V, Dischino DD, Gao Q, Sloan CP, Polson C, Keavy D, Zheng M, Mitroka J, Yeola S. In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor. Curr Drug Metab. 2006 Dec;7(8):883-96. PubMed PMID: 17168689.
5: Anderson JJ, Holtz G, Baskin PP, Turner M, Rowe B, Wang B, Kounnas MZ, Lamb BT, Barten D, Felsenstein K, McDonald I, Srinivasan K, Munoz B, Wagner SL. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol. 2005 Feb 15;69(4):689-98. Epub 2005 Jan 7. PubMed PMID: 15670587.